Thursday, November 5, 2009

Indian drug cos need to focus on niche segments in US generic market: Pharmexcil Study

The Indian pharma companies should focus more on complex chemistry, biotech-based medicines and advance formulations to tap the lucrative US generic market in future, suggests a study conducted by Pharmaceuticals Exports Promotion Council (Pharmexcil) – the apex body governing pharma exports under the Union Ministry of Commerce.

The details can be read here.

No comments: